SCHEMBL1532142

SCHEMBL1532142

CCCCCCOc1ccc(C(=O)Oc2ccc(O)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.72
NPC1 O15118 3/20 0.72
NFKB1 P19838 3/20 0.72
NFKB2 Q00653 3/20 0.72
RELA Q04206 3/20 0.72
SMN1; SMN2 Q16637 3/20 0.72
NR5A1 Q13285 1/20 0.71
CYP1A2 P05177 2/20 0.70
CYP2D6 P10635 2/20 0.70
CYP2C19 P33261 2/20 0.70
CYP3A4 P08684 1/20 0.70
CYP2C9 P11712 1/20 0.70
TSHR P16473 2/20 0.63
TP53 P04637 1/20 0.63
MAPT P10636 2/20 0.62
LTA4H P09960 2/20 0.62
POLB P06746 1/20 0.62
PLA2G4B P0C869 1/20 0.61
PRSS1 P07477 1/20 0.61
ACR P10323 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9647625 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL5482347 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL9744746 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL5185777 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL9650301 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL11315675 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL8943247 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL9737668 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL1934741 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA
SCHEMBL27974007 1.00 LMNA (0.72) LMNANPC1NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2698413-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2016-12-28 EP disclosed
EP-2698412-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2016-10-12 EP disclosed
CN-102112579-B Mesogen-containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-10-29 CN disclosed
EP-2303987-B9 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2014-09-10 EP disclosed
EP-2303987-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2014-03-26 EP disclosed
EP-2698412-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
EP-2698413-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
EP-2698411-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
CN-102112579-A Mesogen-containing compounds TRANSITIONS OPTICAL INC 2011-06-29 CN disclosed
EP-2303987-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2011-04-06 EP disclosed
US-7910019-B2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2011-03-22 US disclosed
US-20090326186-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-31 US disclosed
US-20090323011-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-31 US disclosed
WO-2009158483-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326186-A1 MESOGEN CONTAINING COMPOUNDS MYOC, BMP2, RARG LMNA 1261/4885NPC1 4254/4885NFKB1 3787/4885
US-20090323011-A1 MESOGEN CONTAINING COMPOUNDS MYOC, BMP2, RARG LMNA 1261/4885NPC1 4254/4885NFKB1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.